BioSpace News Archive

Business

eTheRNA opens state-of-the-art manufacturing facility in Belgium to support the development of its TriMix-based mRNA cancer immunotherapies

eTheRNA immunotherapies announces the opening of a state-of-the-art mRNA manufacturing facility enabling the production of mRNA immunotherapies.

October 9, 2018
·
4 min read
Bio NC

Article Focuses on Clinical Study on Safety, Effectiveness of Groundbreaking Health Informatics Technology

IMPATHIQ is pleased to announce the American Heart Association journal Circulation has recently featured the company’s Heart Pathway point-of-care clinical decision support tool.

October 9, 2018
·
4 min read
Bio NC

EpiCypher SNAP-ChIP® technology poised to transform market for histone PTM antibodies

A recently published report in Molecular Cell validates the use of EpiCypher’s proprietary SNAP-ChIP® technology for profiling antibody specificity and sensitivity.

October 9, 2018
·
1 min read
Shaking up how nursing homes and their clinicians are paid to care for sick residents

Keeping frail older adults in a familiar place with staff and providers who know them

October 9, 2018
·
4 min read
Drug Development

Patient Death and Life-Threatening Side Effects Cause Affimed to Hold Phase I Cancer Trials

Affimed, based in Heidelberg, Germany, placed a clinical hold on its two AFM11 Phase I clinical trials. AFM11 is being evaluated in the trials for relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia.

October 9, 2018
·
2 min read
·
Mark Terry
FDA

Four Life Science Companies Make Time’s Genius List

In looking at companies that are shaping the future, Time Magazine selected 50 business that are leading the charge. While many tech companies lead the way, there are several pharma and life science companies that are also disrupting the future.

October 9, 2018
·
2 min read
·
Alex Keown
Deals

Gene Therapy Company MeiraGTx Buys Vector Neurosciences for Its Phase II Parkinson’s Product

MeiraGTx, headquartered in London, UK, acquired Vector Neurosciences in an all-stock deal. As part of the deal, MeiraGTx picks up Vector’s Phase II gene therapy program for Parkinson’s disease.

October 9, 2018
·
2 min read
·
Mark Terry
Business

Novartis to Launch Innovation Labs Across the Globe, Including Silicon Valley

To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.

October 9, 2018
·
2 min read
·
Alex Keown
Business

Merck’s Frazier Joins Growing List of Pharma CEOs Attacking Drug Rebates

Kenneth Frazier, chief executive officer of Merck, speaking with the Economic Club of New York, joined a growing list of pharmaceutical chiefs in criticizing the role of middlemen in rising drug prices.

October 9, 2018
·
3 min read
·
Mark Terry
Drug Development

Landmark Study: Researchers Cure Lethal Disease in Prenatal Mice Using CRISPR

CRISPR, the gene editing technique that scientists claim will lead to the cure and prevention of countless diseases and disorders, took a big step in that direction. Researchers at Children’s Hospital of Philadelphia (CHOP) used CRISPR to prevent a deadly metabolic disorder in prenatal laboratory animals.

October 9, 2018
·
3 min read
·
Mark Terry